Literature DB >> 11815431

Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms.

Tom W G Carrell1, Kevin G Burnand, Graham M A Wells, John M Clements, Alberto Smith.   

Abstract

BACKGROUND: Atherosclerosis is implicated in the pathogenesis of abdominal aortic aneurysm (AAA) but more often causes aortic occlusive disease (AOD). The matrix metalloproteinases (MMPs) degrade extracellular matrix and may play a central role in the pathogenesis of AAA. The aim of this study was to examine differences in the patterns of MMP and MMP inhibitor expression between AAA and AOD. METHODS AND
RESULTS: The expression of mRNA for 14 MMPs and 4 tissue inhibitors of metalloproteinases (TIMPs) was estimated in samples of aortic wall from 8 patients with AAA and 8 with AOD using the reverse-transcriptase polymerase chain reaction with a synthetic multicompetitor standard. AAA wall expressed significantly more stromelysin-1 (MMP-3) (mean log(10) ratio [copy enzyme cDNA/copy GAPDH cDNA], -1.9; range, -3.3 to -0.7) than the AOD wall (mean, 4; range, -5.7 to -2.4), P<0.005. TIMP-3 expression was significantly higher in AAA (mean, -1.7; range, -2.9 to -1.0) than AOD (mean, -3.6; range, -5.7 to -1.8), P<0.01. Expression of 8 other MMPs (1, 2, 7, 9, 11, 12, 14, and 17) was detected and was similar in AAA and AOD. Expression of the remaining 5 MMPs (-8, -10, -13, -15, and -16) was not detected in any of the samples.
CONCLUSIONS: Both AAA and AOD walls express similar levels of a wide range of MMPs, including cell membrane-bound MT-MMPs. Stromelysin-1 (MMP-3) and TIMP-3 were, however, over expressed in the AAA samples and may be involved aneurysm pathogenesis. Stromelysin-1 could provide a target for pharmacological inhibition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815431     DOI: 10.1161/hc0402.102621

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  28 in total

Review 1.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

2.  Mast cell tryptase deficiency attenuates mouse abdominal aortic aneurysm formation.

Authors:  Jie Zhang; Jiusong Sun; Jes S Lindholt; Galina K Sukhova; Mark Sinnamon; Richard L Stevens; Roberto Adachi; Peter Libby; Robert W Thompson; Guo-Ping Shi
Journal:  Circ Res       Date:  2011-04-14       Impact factor: 17.367

3.  Direct relationship between cell density and FDG uptake in asymptomatic aortic aneurysm close to surgical threshold: an in vivo and in vitro study.

Authors:  Cecilia Marini; Silvia Morbelli; Riccardo Armonino; Giovanni Spinella; Mattia Riondato; Michela Massollo; Francesca Sarocchi; Bianca Pane; Carla Augeri; Luca Abete; Giorgio Ghigliotti; Daniela Palmieri; Francesco Fiz; Giuseppe Cittadini; Ezio Fulcheri; Domenico Palombo; Gianmario Sambuceti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-10-20       Impact factor: 9.236

4.  Matrix metalloprotease-3 and tissue inhibitor of metalloprotease-1 mRNA and protein levels are altered in response to traumatic skeletal muscle injury.

Authors:  Maria L Urso; Eric R Szelenyi; Gordon L Warren; Brian R Barnes
Journal:  Eur J Appl Physiol       Date:  2010-03-27       Impact factor: 3.078

5.  Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms.

Authors:  Vincent Fontaine; Marie-Paule Jacob; Xavier Houard; Patrick Rossignol; Didier Plissonnier; Eduardo Angles-Cano; Jean-Baptiste Michel
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

6.  Non-invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA(3)CT): Design of a Phase IIb, placebo-controlled, double-blind, randomized clinical trial of doxycycline for the reduction of growth of small abdominal aortic aneurysm.

Authors:  B Timothy Baxter; Jon Matsumura; John Curci; Ruth McBride; William C Blackwelder; Xinggang Liu; LuAnn Larson; Michael L Terrin
Journal:  Contemp Clin Trials       Date:  2016-03-25       Impact factor: 2.226

Review 7.  MEMBRANE TYPE 1-MATRIX METALLOPROTEINASE (MT1-MMP) IDENTIFIED AS A MULTIFUNCTIONAL REGULATOR OF VASCULAR RESPONSES.

Authors:  Hiroshi Ohkawara; Kazuhiko Ikeda; Kazuei Ogawa; Yasuchika Takeishi
Journal:  Fukushima J Med Sci       Date:  2015-09-11

8.  The transcriptional programme of human heart valves reveals the natural history of infective endocarditis.

Authors:  Marie Benoit; Franck Thuny; Yannick Le Priol; Hubert Lepidi; Sonia Bastonero; Jean-Paul Casalta; Frédéric Collart; Christian Capo; Didier Raoult; Jean-Louis Mege
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

Review 9.  Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm.

Authors:  Faisal Aziz; Helena Kuivaniemi
Journal:  Ann Vasc Surg       Date:  2007-05       Impact factor: 1.466

Review 10.  Digging in the "soil" of the aorta to understand the growth of abdominal aortic aneurysms.

Authors:  John A Curci
Journal:  Vascular       Date:  2009 May-Jun       Impact factor: 1.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.